About NRx
NRx is a company based in Wilmington (United States) founded in 2017 by Daniel C Javitt and Jonathan C Javitt. NRx operates in a competitive market with competitors including Pardes Biosciences, Vaxxinity, ExeVir Bio, Inimmune and IMUNON, among others.
- Headquarter Wilmington, United States
- Founders Daniel C Javitt, Jonathan C Javitt
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nrx Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$25.13 M (USD)16.66as on Dec 31, 2024
-
EBITDA
-$19.7 M (USD)28.58as on Dec 31, 2024
-
Latest Funding Round
$25 M (USD), Post-IPO
Feb 02, 2022
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NRx
NRx is a publicly listed company on the NASDAQ with ticker symbol NRXP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of NRx
Unlock access to complete
Unlock access to complete
Funding Insights of NRx
Investors in NRx
NRx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for NRx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NRx
Investment portfolio details for NRx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NRx
Detailed financials for NRx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nrx Comparisons
Peer comparison for NRx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NRx
NRx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pardes Biosciences, Vaxxinity, ExeVir Bio, Inimmune and IMUNON, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for pandemic diseases including SARS-CoV-2 are developed.
|
|
| Locked | Locked | Locked |
Vaccines for neurological disorders and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Provider of antibody-based therapies to monitor viral infections
|
|
| Locked | Locked | Locked |
Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed using DNA-based platforms.
|
Detailed competitors of NRx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nrx
Complete news archive for NRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NRx
NRx was founded in 2017.
NRx is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Jonathan C Javitt is the current CEO of NRx. They have also founded this company.
NRx was founded in 2017 and is headquartered in Wilmington, United States. Therapeutics targeting COVID-19 and neurological disorders are developed by the company within the pharmaceutical sector. Operations focus on candidates such as ZYESAMI, which contains aviptadil acetate for respiratory failure in COVID-19, along with NRX-101 and NRX-100 for acute suicidal behavior in bipolar disorder. Clinical development and regulatory processes are managed from the U.S. base.
NRx's top competitors include ExeVir Bio, Cell BioEngines and Pardes Biosciences.
Yes, NRx is publicly traded on NASDAQ under the ticker symbol NRXP.
NRx has 1 investor. Key investors include HHS.
The ticker symbol of NRx is NRXP on NASDAQ.
The valuation of NRx is $1.5B as of Aug 2021.